COUR Pharmaceuticals
Disclosure information not submitted.
Induction of Antigen-Specific T Cell Tolerance by CNP-104 Positively Affects Clinical Response in Primary Biliary Cholangitis (PBC)
Thursday, June 26, 20254:40pm - 4:55pm East Coast USA Time
